Jaguar Health, Inc. (NASDAQ:JAGX) is hosting a special media event and performance in New York City on Monday, May 23rd, 2022 from 12:30 to 2:30 PM Eastern to celebrate the launch of the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) initiative - the first-ever U.S. Canine Cancer Registry and Cancer Care index - because protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location.
"This is a special event for ALL interested parties - dog owners, veterinarians, veterinary oncology specialists, investors, the media, and anyone who is concerned about addressing and managing cancer in our four-legged best friends - and the event is taking place on the first annual National Canine Cancer Awareness Day!" said Lisa Conte, Jaguar Health's founder, president, and CEO. "This first-ever U.S. Canine Cancer Registry and Cancer Care Index is being created to assess the prevalence and incidence of cancer in dogs. We will be revealing data at the event from the first nationwide Gallup survey of pet owners addressing their experience with canine cancer, as well as the registry itself that is based on the analysis of thousands of anonymized canine medical records. The data may also provide insights to help better understand cancer in humans as well."
To RSVP to attend this in-person, outdoor event, click here or send an email to This email address is being protected from spambots. You need JavaScript enabled to view it.. This event will also be live streamed here on the Take C.H.A.R.G.E. Facebook page for parties unable to attend in person.
Take C.H.A.R.G.E. is co-sponsored by TogoRun and Ivee (Intelligent Veterinary Enhanced Experience).
WHO:
WHERE:
Madison Square Park
Enter at 23rd Street and Broadway, New York, NY 10010
WHEN:
Monday, May 23rd, 2022
12:30 - 2:30 p.m. EDT
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar Health will host a launch event May 23, 2022 for the Take C.H.A.R.G.E. initiative. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
*Swag items will be available on a first-come, first-served basis and supplies are limited
**Artists subject to change
TakeCharge is a registered trademark of H. Lee Moffitt Cancer Center and Research Institute, Inc.
Contact:
Peter Hodge
Jaguar Health, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jaguar-JAGX
Media Contact
Dawn Maniglia
TogoRun
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-862-5444
Last Trade: | US$0.96 |
Daily Change: | 0.09 9.95 |
Daily Volume: | 556,029 |
Market Cap: | US$11.330M |
December 19, 2024 December 18, 2024 December 17, 2024 December 13, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB